You are here: Industry Insights > biosimilars

News List

Monoclonal antibody drugs in development in China Xiaoyaowan
November 14, 2018
there have been 4 Chinese pharmaceutical enterprises that have filed the marketing applications...
Amazing Monthly Sales Performance of Opdivo and Keytruda in China Xiaoyaowan
November 06, 2018
It was revealed that by September 30, i.e., about one month after the marketing in China, the sales revenue of the two anti-PD-1 monoclonal antibody drugs: Opdivo and Keytruda separately reached RMB 190 million and RMB 150 million, showing amazing perform
Biosimilars of the “Drug King” Humira being marketed, eroding the Global Sales of the Original Drug! Zhixing
October 25, 2018
Humira is a well-deserved drug king as it had been staying on the position of top of global best-selling drugs for six c
Dong-A Pharma diversifies portfolio to include biosimilars biospectrumasia
October 24, 2018
BioSpectrum Asia Top 20 Survey Rank 16 - Dong-A Pharmaceutical, South Korea
Amgen, Novartis first to launch Humira biosimilars in Europe biospectrumasia
October 17, 2018
Tags: Top Story Amgevita Humira Hyrimoz AbbVie Amgen Novartis Arthritis IBD Psoriasis General Practice Internal Medicine Marketing & Sales
Biosimilars market to increase to $61.47 billion europeanpharmaceuticalreview
September 26, 2018
A report has suggested that the biosimilars market growth will increase at a CAGR of 34.2 percent over the course of the period analysed…
With EU salivating after Humira biosims, analysts start questioning AbbVie's optimism fiercepharma
September 17, 2018
Humira biosimilars will hit the European market next month, but AbbVie executives are still soft-pedaling the threat to their top line. CEO Rick Gonzalez and his colleagues say they'll match competitors on price to keep Humira's market-leading position.
Government looks to include biosimilars in price controls pharmatimes
August 08, 2018
The government has launched consultation on proposed changes to the statutory scheme for pharmaceutical pricing that would include biosimilars in the scope of its price controls.
Biosimilars and generics saved NHS £324m last year pharmafile
August 03, 2018
The NHS watchdog, NHS Improvement, has revealed that the British National Health Service saved £324 million last financial year by using more cost effective biosimilars and generics, instead of more costly alternatives. The watchdog noted that the biosimi
Spooked AbbVie investors are selling off shares—but do they need to be? fiercepharma
July 23, 2018
AbbVie investors are running for the exits after comments on biosimilars from the FDA head, proposed rebate rule changes from the Trump administration and an ominous short-seller tweet. But they don’t need to be, industry watchers say.

Previous page 1 2 3 4 5 6 Next page